SpringerLink
Log in

Novel Therapies in the Treatment of Hodgkin Lymphoma

  • Lymphoma (JL Muñoz, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Patients with Hodgkin lymphoma (HL) can achieve excellent response and survival rates following frontline combination chemo- and radiation therapy. However, about 10–15% of patients will experience disease relapse which is associated with poor outcomes. Recent breakthroughs in understanding the mechanisms of oncogenicity and interactions within the tumor microenvironment have resulted in development of novel drugs for treatment of patients with HL. Utilizing this information, treatment of newly diagnosed and relapsed HL has become a rapidly evolving field with multiple clinical trials evaluating novel treatment approaches incorporating targeted immunotherapy. In the frontline setting, the use of novel drugs may allow for de-escalation of therapy to avoid long-term complications associated with bleomycin and consolidation radiation therapy. Patients with early-stage, non-bulky disease are candidates for omitting radiation therapy using treatment combinations that include upfront use of brentuximab vedotin or nivolumab. In patients with advanced disease, the addition of brentuximab vedotin to a chemotherapy backbone is currently the standard of care in our practice, particularly in patients with a contraindication for receiving bleomycin. Future investigations in patients with advanced-stage HL will focus on establishing a new standard of care by comparing brentuximab vedotin and nivolumab in combination with chemotherapy (BV-AVD vs. N-AVD) and decreasing the risk of relapse by exploring consolidation therapy in patients with high-risk disease. In patients who have relapsed or are refractory to first-line therapy, salvage treatment has incorporated brentuximab vedotin or PD-1 checkpoint inhibitors to improve response rates of cytotoxic chemotherapy thereby improving the probability of a successful stem cell transplant. Post-transplant consolidation with brentuximab is currently standard of care in patients with high-risk disease. Patients who relapse following autologous stem cell transplant now have an expanded armamentarium of chemo- and immunotherapy options. However, the challenge is to determine the sequence of therapy after prior brentuximab or checkpoint inhibitor exposure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.

    Article  Google Scholar 

  2. Küppers R. Molecular biology of Hodgkin lymphoma. Hematology. 2009;2009(1):491–6. https://doi.org/10.1182/asheducation-2009.1.491.

    Article  Google Scholar 

  3. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–7. https://doi.org/10.1038/299065a0.

    Article  CAS  PubMed  Google Scholar 

  4. Stein H, Uchánska-Ziegler B, Gerdes J, Ziegler A, Wernet P. Hodgkin and Sternberg-Reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982;29(3):283–90. https://doi.org/10.1002/ijc.2910290310.

    Article  CAS  PubMed  Google Scholar 

  5. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32. https://doi.org/10.1182/blood-2011-01-293050.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Journal of Clinical Oncology. 2011;29(14):1812–26. https://doi.org/10.1200/jco.2010.32.8401.

    Article  CAS  PubMed  Google Scholar 

  7. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–7. https://doi.org/10.1200/jco.2016.66.4482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56. https://doi.org/10.1016/s1470-2045(13)70501-1.

    Article  CAS  PubMed  Google Scholar 

  9. Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, et al. ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther. 2016;15(11):2709–21. https://doi.org/10.1158/1535-7163.MCT-16-0233.

    Article  CAS  PubMed  Google Scholar 

  10. • Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine. 2014;372(4):311–9. https://doi.org/10.1056/NEJMoa1411087 Phase I trial evaluating efficacy of nivolumab in patients with relapsed Hodgkin lymphoma.

    Article  CAS  PubMed  Google Scholar 

  11. • Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–9. https://doi.org/10.1200/jco.2016.67.3467 Initial phase I trial evaluating efficacy of pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32(3):163–8. https://doi.org/10.1200/jco.2013.53.1194.

    Article  CAS  PubMed  Google Scholar 

  13. National Comprehensive Cancer Network. Hodgkin lymphoma (Version 2.2020). 2020. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed November 2, 2020.

  14. • Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019;134(7):606–13. https://doi.org/10.1182/blood.2019001272 Phase I/II trial evaluating brentuximab vedotin in addition to doxorubicin, vinblastine, and dacarbazine in patients with early-stage Hodgkin lymphoma.

    Article  CAS  PubMed  Google Scholar 

  15. Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, et al. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020;4(11):2548–55. https://doi.org/10.1182/bloodadvances.2020001871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Brockelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020;6(6):872–80. https://doi.org/10.1001/jamaoncol.2020.0750 Randomized phase II trial showing efficacy of nivolumab in addition to standard chemotherapy for patients with early-stage Hodgkin lymphoma.

    Article  PubMed  Google Scholar 

  17. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331–44. https://doi.org/10.1056/NEJMoa1708984 Randomized phase III trial comparing BV-AVD to AVBD leading to approval of brentuximab vedotin for patients with Hodgkin lymphoma.

    Article  CAS  PubMed  Google Scholar 

  18. Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135(10):735–42. https://doi.org/10.1182/blood.2019003127.

    Article  PubMed  Google Scholar 

  19. • Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study. J Clin Oncol. 2019;37(23):1997–2007. https://doi.org/10.1200/jco.19.00315 Randomized phase II multicenter trial using nivolumab followed by nivolumab+AVD.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005–15. https://doi.org/10.1182/blood-2011-12-396556.

    Article  CAS  PubMed  Google Scholar 

  21. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692–5. https://doi.org/10.1182/blood-2011-09-378414.

    Article  CAS  PubMed  Google Scholar 

  22. • Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–804. https://doi.org/10.1182/blood-2015-06-644336 Phase II trial showing efficacy of brentuximab monotherapy in patients with Hodgkin lymphoma who were ineligible for conventional chemotherapy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, et al. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). Br J Haematol. 2020. https://doi.org/10.1111/bjh.17073.

  24. Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015–22. https://doi.org/10.1200/jco.2018.79.0139.

    Article  CAS  PubMed  Google Scholar 

  25. Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020;7(11):e808–e15. https://doi.org/10.1016/s2352-3026(20)30275-1.

    Article  PubMed  Google Scholar 

  26. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–4. https://doi.org/10.1016/0140-6736(93)92411-l.

    Article  CAS  PubMed  Google Scholar 

  27. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17(2):534–45. https://doi.org/10.1200/jco.1999.17.2.534.

    Article  CAS  PubMed  Google Scholar 

  28. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. The Lancet Oncology. 2015;16(3):284–92. https://doi.org/10.1016/s1470-2045(15)70013-6.

    Article  CAS  PubMed  Google Scholar 

  29. Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica. 2020. https://doi.org/10.3324/haematol.2019.243238.

  30. Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018;29(3):724–30. https://doi.org/10.1093/annonc/mdx791.

    Article  CAS  PubMed  Google Scholar 

  31. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–94. https://doi.org/10.1182/blood-2017-10-811224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Hancock H, Davey T, et al. Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. Blood. 2020;136(Supplement 1):17–8. https://doi.org/10.1182/blood-2020-138434.

    Article  Google Scholar 

  33. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–8. https://doi.org/10.1182/blood-2017-11-815183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. The Lancet. 2002;359(9323):2065–71. https://doi.org/10.1016/s0140-6736(02)08938-9.

    Article  CAS  Google Scholar 

  35. •• Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146(2):158–63. https://doi.org/10.1111/j.1365-2141.2009.07727.x Large phase III trial evaluating post-autologous stem cell transplant consolidation with brentuximab vedotin in patients with high risk of Hodgkin lymphoma.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62. https://doi.org/10.1016/s0140-6736(15)60165-9.

    Article  CAS  PubMed  Google Scholar 

  37. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–42. https://doi.org/10.1182/blood-2018-07-861641.

    Article  CAS  PubMed  Google Scholar 

  38. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston PB, Mei M, et al. Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma. Blood. 2020;136(Supplement 1):19–20. https://doi.org/10.1182/blood-2020-136384.

    Article  Google Scholar 

  39. •• Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–32. https://doi.org/10.1200/jco.2016.72.1316 Phase II trial that established the efficacy of pembrolizumab in patients with Hodgkin lymphoma.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–53. https://doi.org/10.1182/blood.2019000324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–39. https://doi.org/10.1200/jco.2017.76.0793.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660–e70. https://doi.org/10.1016/s2352-3026(20)30221-0.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–e9. https://doi.org/10.1016/s2352-3026(18)30192-3.

    Article  PubMed  Google Scholar 

  44. Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020;34(2):533–42. https://doi.org/10.1038/s41375-019-0545-2.

    Article  CAS  PubMed  Google Scholar 

  45. Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 2019;25(24):7363–9. https://doi.org/10.1158/1078-0432.Ccr-19-1680.

    Article  CAS  PubMed  Google Scholar 

  46. Herrera AF, Carlo-Stella C, Collins GP, Maddocks KJ, Bartlett NL, Savage KJ, et al. Preliminary results of a phase 2 study of camidanlumab tesirine (Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(Supplement 1):21–3. https://doi.org/10.1182/blood-2020-137451.

    Article  Google Scholar 

  47. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. https://doi.org/10.1056/NEJMoa1804980.

    Article  CAS  PubMed  Google Scholar 

  48. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42. https://doi.org/10.1056/NEJMoa1914347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156–66. https://doi.org/10.1158/1078-0432.CCR-16-1365.

    Article  CAS  PubMed  Google Scholar 

  51. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020:Jco2001342. https://doi.org/10.1200/jco.20.01342 Pooled analysis of two phase I/II trials using antiCD30 CAR-T for patients with relapsed and refractory Hodgkin lymphoma.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Xavier Andrade-Gonzalez MD & Stephen M. Ansell MD, PhD

Authors
  1. Xavier Andrade-Gonzalez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen M. Ansell MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen M. Ansell MD, PhD.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

Dr. Andrade-Gonzalez declares that he has no conflict of interest. Dr Ansell receives research funding (to his institution) from the Bristol Myers Squibb, Seattle Genetics, Takeda, Regeneron, ADC Therapeutics, Affimed, Trillium, and AI Therapeutics.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Andrade-Gonzalez, X., Ansell, S.M. Novel Therapies in the Treatment of Hodgkin Lymphoma. Curr. Treat. Options in Oncol. 22, 42 (2021). https://doi.org/10.1007/s11864-021-00840-5

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00840-5

Keywords

Search

Navigation